Preview

Артериальная гипертензия

Расширенный поиск

Антагонисты рецепторов к ангиотензину II 1 типа при сердечно-сосудистых заболеваниях: место валсартана

https://doi.org/10.18705/1607-419X-2011-17-4-325-332

Полный текст:

Аннотация

Статья посвящена особенностям и механизмам антигипертензивного и органопротективного действия антагониста рецепторов к ангиотензину II 1-го типа валсартана, а также его клиническому применению при сердечно-сосудистых заболеваниях.

Об авторах

Ю. В. Свиряев
ФГУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова»
Россия


Н. Э. Звартау
ФГУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова»
Россия


Список литературы

1. Tigerstedt R., Bergman P. Niere und Kreislauf // Skand. Arch. Physiol. - 1898. - Vol. 8. - P. 223-271.

2.

3. Skeggs L.T. Jr, Lentz K.E., Kahn J.R., Shumway N.P., Woods K.R. The amino acid sequence of hypertensin // II J. Exp. Med. - 1956. - Vol. 104. - P. 193-197.

4.

5. Kageyama R., Ohkubo H., Nakanishi S. Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence // Biochemistry. - 1984. - Vol. 23, № 16. - P. 3603-3609.

6.

7. Braun-Menendez E., Page I.H. Suggested revision of nomenclature - angiotensin // Science. - 1958. - Vol. 127. - P. 242.

8.

9. Braun-Menendez E., Fasciolo J.C., Leloir L.F., Muñoz J.M. The substance causing renal hypertension // J. Physiol. - 1940. - Vol. 98, № 3. - P. 283-298.

10.

11. Page I.H., Helmer O.M. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator // J. Exp. Med. - 1940. - Vol. 71, № 1. - P. 29-42.

12.

13. Skeggs L.T. Jr, Marsh W.H., Kahn J.R., Shumway N.P. The existence of two forms of hypertension // J. Exp. Med. - 1957A. - Vol. 99, № 3. - P. 275-282.

14.

15. Gross F. Renin und hypertensin, physiologische oder pathologische Wirkstoffe? // Klin. Wochenschr. - 1958. - Vol. 36. - P. 693-706.

16.

17. Davis J.O. Mechanisms regulating the secretion and metabolism of aldosterone in experimental secondary hyperaldosteronism // Recent Prog. Horm. Res. - 1959. - Vol. 17. - P. 293-352.

18.

19. Skeggs L.T., Dorer F.E., Kahn J.R., Lentz K.E., Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension // Am. J. Med. - 1976. - Vol. 60, № 6. - P. 737-748.

20.

21. Dzau V.J. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis // Hypertension. 2001. Vol. 37, № 4. P. 10471052. <http://www.ncbi.nlm.nih.gov/pubmed/11304501>

22.

23. Lemarie C.A., Paradis P., Schiffrin E.L. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone // J. Mol. Med. - 2008. - Vol. 86, № 6. - P. 673-678.

24.

25. Furuhashi M., Ura N., Takizawa H. et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity // J. Hypertens. - 2004. - Vol. 22, № 10. - P. 1977-1982.

26.

27. Jandeleit-Dahm K.A., Tikellis C., Reid C.M. et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes // J. Hypertens. - 2005. - Vol. 23, № 3. - P. 463-473.

28.

29. Kingston R. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity // J. Hypertens. - 2004. - Vol. 22, № 10. - P. 1867-1868.

30.

31. Kurtz T.W., Klein U. Next generation multifunctional angiotensinreceptor blockers // Hypertens. Res. - 2009. - Vol. 32, № 10. -P. 826-834.

32.

33. Miura S., Fujino M., Hanzawa H. et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor // J. Biol. Chem. - 2006. - Vol. 281, № 28. - Р. 19288-19295.

34.

35. Miura S., Kiya Y., Kanazawa T. et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state // Mol. Endocrinol. - 2008. - Vol. 22, № 1. - P. 139-146.

36.

37. Zou Y., Akazawa H., Qin Y. et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II // Nat. Cell. Biol. - 2004. - Vol. 6, № 6. - P. 499-506.

38.

39. Inada Y., Ojima M., Kanagawa R. et al. Pharmacologic properties of candesartan cilexetil - possible mechanisms of long-term antihypertensiveaction // J. Hum. Hypertens. - 1999. - Vol. 13, Suppl. 1. - P. 75-80.

40.

41. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis // Annu Rev. Immunol. - 2009. - Vol. 27. - P. 165-197.

42.

43. Scott J. The pathogenesis of atherosclerosis and new opportunities for treatment and prevention // J. Neural Transm. Suppl. - 2002. - № 63. - Р. 1-17.

44.

45. Li J.J., Chen J.L. Inflammation may be a bridge connecting hypertension and atherosclerosis // Med. Hypotheses. - 2005. - Vol. 64, № 5. - Р. 925-929.

46.

47. Dandona P., Kumar V., Aljada A. et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action // J. Clin. Endocrinol. Metab. - 2003. - Vol. 88, № 9. - Р. 4496-4501.

48.

49. Manabe S., Okura T., Watanabe S., Fukuoka T., Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension // J. Cardiovasc. Pharmacol. - 2005. - Vol. 46, № 6. - P. 735-739.

50.

51. Ogawa S., Mori T., Nako K. et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy // Hypertension. - 2006. -Vol. 47. - P. 699-705.

52.

53. Cianchetti S., Del Fiorentino A., Colognato R. et al. Anti-inflammatory and antioxidant properties of telmisartan in cultured human umbilical vein endothelial cells // Atherosclerosis. - 2008. - Vol. 198, № 1. - P. 22-28.

54.

55. Guerra-Cuesta J.I., Montуn M., Rodrнguez-Feo J.A. et al. Effect of losartan on human platelet activation // J. Hypertens. - 1999. - Vol. 17, № 3. - P. 447-452.

56.

57. Singh R., Singh A.K., Alavi N., Leehey D.J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose // J. Am. Soc. Nephrol. - 2003. - Vol. 14, № 4. - P. 873-880.

58.

59. Konstam M.A., Patten R.D., Thomas I. et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure. Results of the ELITE ventricular function substudy // Am. Heart J. - 2000. - Vol. 139, № 6. - P. 1081-1087.

60.

61. McDonald K.M., Garr M., Carlyle P.F. et al. Relative effects of a1-adrenergic blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog // Circulation. - 1994. - Vol. 90, № 6. - P. 3034-3046.

62.

63. Pourdjabbar A., Parker T.G., Nguyen Q.T. et al. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: Effect of dose on survival, ventricular arrhythmias, function and remodeling // Am. J. Physiol. Heart Circ. Physiol. - 2005. - Vol. 288, № 4. - P. H1997-H2005.

64.

65. Sawicki G., Menon V., Jugdutt B.I. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade // J. Cardiac Fail. - 2004. - Vol. 10, № 5. - P. 442-449.

66.

67. Solomon S.D., Skali H., Anavekar N.S. et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction // Circulation. - 2005. - Vol. 111, № 25. - P. 3411-3419.

68.

69. Wachtell K., Okin P.M., Olsen M.H. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study // Circulation. - 2007. - Vol. 116, № 7. - P. 700-705.

70.

71. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension // Am. J. Med. - 2003. - Vol. 115, № 1. -P. 41-46.

72.

73. Neutel J <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Weber M <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Pool J <http://www.ncbi.nlm.nih.gov/pubmed?term=>. et al. Valsartan, a new angiotensin II an tagonist: antihypertensive effects over 24 hours // Clin. Ther. <http://www.ncbi.nlm.nih.gov/pubmed/9220209> - 1997. - Vol. 19, № 3. - P. 447-458; discussion 367-368.

74.

75. Hermida R.C <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Calvo C <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Ayala D.E <http://www.ncbi.nlm.nih.gov/pubmed?term=>. et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects // Hypertension. <http://www.ncbi.nlm.nih.gov/pubmed/12874091> - 2003. - Vol. 42, № 3. - Р. 283-290.

76.

77. Berdecchia P., Porcellati C., Schillaci G. et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension // Hypertension. - 1994. -Vol. 24, № 6. - P. 793-801.

78.

79. Staessen J.A., Thijs L., Fagard R. et al., for the Systolic Hypertension in Europe (Syst-Eur) trial investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension // J. Am. Med. Assoc. - 1999. - Vol. 282, № 6. - P. 539-546.

80.

81. Ohkubo T., Hozawa A., Yamaguchi J. et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study // J. Hypertens. - 2002. - Vol. 20, № 11. - P. 2183-2189.

82.

83. Mclnnes G.T. Angiotensin II antagonism in clinical practice: experience with valsartan // J. Cardiovasc. Pharmacol. - 1999. - Vol. 33, Suppl. 1. - P. 29-32.

84.

85. Malacco E., Santonastaso M., Vari N.A. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study // Clin. Ther. - 2004. - Vol. 26, № 6. - P. 855-865.

86.

87. Viberti G., Wheeldon N.M., for the (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect // Circulation. - 2002. - Vol. 106, № 6. - P. 672−678.

88.

89. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2022-2031.

90.

91. Vaney C., Waeber B., Turini G., Margalith D., Brunner H.R., Perret C. Renin and the complications of acute myocardial infarction // Chest. - 1984. - Vol. 86, № 1. - P. 40-43.

92.

93. Remes J. Neuroendocrine activation after myocardial infarction // Br. Heart J. - 1994. - Vol. 72, № 3, Suppl.. - P. S65-S69.

94.

95. Isnard R., Pousset F., Trochu J. et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure // Am. J. Cardiol. - 2000. - Vol. 86, № 4. - P. 417-421.

96.

97. Perondi R., Saino A., Tio R.A. et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease // Circulation. - 1992. - Vol. 85, № 6. - P. 2004-2013.

98.

99. Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection // Circulation. - 1994. - Vol. 90, № 4. - P. 2056-2069.

100.

101. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system // Circulation. - 1991. - Vol. 83, № 6. - P. 1849-1865.

102.

103. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both // N. Engl. J. Med. - 2003. - Vol. 349, № 20. - P. 1893-1906.

104.

105. White H.D., Aylward P.E., Huang Z. et al.; VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial <http://www.ncbi.nlm.nih.gov/pubmed/16301343> (VALIANT) // Circulation. - 2005. - Vol. 112, № 22. - Р. 3391-3399.

106.

107. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure // J. Am. Coll. Cardiol. - 1992. - Vol. 20, № 1. - P. 248-254.

108.

109. Benedict C.R., Johnstone D.E., Weiner D.H. et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD investigators // J. Am. Coll. Cardiol. - 1994. - Vol. 23, № 6. - P. 1410-1420.

110.

111. Cohn J.N., Tognoni G., Valsartan Heart Failure Trial Investigators.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. - 2001. - Vol. 345, № 23. - P. 1667-1675.

112.

113. Latini R., Tognoni G., Maggioni A.P. et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group // J. Am. Coll. Cardiol. - 2000. - Vol. 35, № 7. - P. 1801-1807.

114.

115. Maggioni A.P., Latini R. The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years? // Blood Press. - 2002. - Vol. 11, № 6. - P. 328-338.

116.

117. Cuspidi C., Negri F., Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention // Vasc. Health Risk Manag. - 2008. - Vol. 4, № 1. - P. 67-73.

118.

119. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates // Am. J. Cardiol. - 1998. - Vol. 82, № 8А. - P. 2N-9N.

120.

121. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program // Am. Heart J. - 2006. - Vol. 151, № 5. - P. 985-991.

122.

123. Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart J. - 2005. - Vol. 149, № 3. - P. 548-557.

124.

125. Schmieder R.E., Kjeldsen S.E., Julius S. et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial // J. Hypertens. - 2008. - Vol. 26, № 3. - P. 403-411.

126.

127. GISSI-AF Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation) Valsartan for prevention of recurrent atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 360, № 16. - P. 1606-1617.

128.

129. Wogen J., Kreilick C.A., Livornese R.C., Yokoyama K., Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting // J. Manag. Care Pharm. <http://www.ncbi.nlm.nih.gov/pubmed/14613440> - 2003. - Vol. 9, № 5. - P. 424-429.

130.


Для цитирования:


Свиряев Ю.В., Звартау Н.Э. Антагонисты рецепторов к ангиотензину II 1 типа при сердечно-сосудистых заболеваниях: место валсартана. Артериальная гипертензия. 2011;17(4):325-332. https://doi.org/10.18705/1607-419X-2011-17-4-325-332

For citation:


Sviryaev Y.V., Zvartau N.E. Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(4):325-332. (In Russ.) https://doi.org/10.18705/1607-419X-2011-17-4-325-332

Просмотров: 99


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)